{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:28:19Z","timestamp":1790771299318,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The role of adjuvant therapy (AT) after pancreaticoduodenectomy (PD) for distal cholangiocarcinoma (DC) remains controversial. This systematic review and meta-analysis aimed to evaluate the impact of AT on overall survival (OS) and disease-free survival (DFS) in patients with resected DC. A systematic review was conducted following PRISMA guidelines (PROSPERO: CRD42024561780). PubMed, Scopus, Web of Science, and Cochrane databases were searched for studies published between January 2000 and August 2023. Eligible studies included patients who underwent PD for DC, comparing AT to follow-up (FUP) alone. Primary endpoints were OS and DFS, analyzed using hazard ratios (HR) with 95% confidence intervals (CI). Meta-regression explored potential sources of heterogeneity. The analysis included 22 studies with 7078 patients (3860 FUP group, 3218 AT group): of the studies, only 3 (13.6%) were RCTs (even if none of them was specifically designed for DC). AT significantly improved OS (HR 0.80; 95% CI 0.73\u20130.89;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and DFS (HR 0.84; 95% CI 0.74\u20130.96;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.023) compared to FUP. Subgroup analysis showed a greater benefit for chemo-radiotherapy (OS HR 0.81; 95% CI 0.72\u20130.91) over chemotherapy alone (OS HR 0.78; 95% CI 0.64\u20130.94). High heterogeneity (\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200998%) was identified among the included studies. This meta-analysis demonstrates that AT is associated with improved survival outcomes in patients undergoing PD for DC. However, the significant limitations of the existing literature, particularly the lack of RCTs designed specifically for DC, necessitate caution, especially on which type of chemotherapy should be adopted.\n                  <\/jats:p>","DOI":"10.1007\/s13304-025-02383-y","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T15:44:49Z","timestamp":1756741489000},"page":"275-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does adjuvant therapy improve survival in patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma? A systematic review, meta-analysis and meta-regression"],"prefix":"10.1007","volume":"78","author":[{"given":"G.","family":"Nappo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"D\u2019Ambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6638-4479","authenticated-orcid":false,"given":"C.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pagnanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rebasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2383_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/liv.13998","volume":"39","author":"V Cardinale","year":"2019","unstructured":"Cardinale V (2019) Classifications and misclassification in cholangiocarcinoma. Liver Int 39:260\u2013262","journal-title":"Liver Int"},{"key":"2383_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557\u2013588","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2383_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002064","volume":"94","author":"A Moon","year":"2015","unstructured":"Moon A, Choi DW, Choi SH, Heo JS, Jang KT (2015) Validation of T stage according to depth of invasion and n stage subclassification based on number of metastatic lymph nodes for distal extrahepatic bile duct (EBD) carcinoma. Medicine (Baltimore) 94:e2064","journal-title":"Medicine (Baltimore)"},{"key":"2383_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00595-016-1362-0","volume":"47","author":"UF Wellner","year":"2017","unstructured":"Wellner UF, Shen Y, Keck T, Jin WY, Xu Z (2017) The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today 47:271\u2013279","journal-title":"Surg Today"},{"key":"2383_CR5","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.3390\/curroncol29090524","volume":"29","author":"L Gorji","year":"2022","unstructured":"Gorji L, Beal EW (2022) Surgical treatment of distal cholangiocarcinoma. Curr Oncol 29:6674\u20136687","journal-title":"Curr Oncol"},{"key":"2383_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12893-018-0384-5","volume":"18","author":"O Beetz","year":"2018","unstructured":"Beetz O, Klein M, Schrem H et al (2018) Relevant prognostic factors influencing outcome of patients after surgical resection of distal cholangiocarcinoma. BMC Surg 18:56","journal-title":"BMC Surg"},{"key":"2383_CR7","first-page":"571","volume":"30","author":"J Byrling","year":"2017","unstructured":"Byrling J, Andersson R, Sasor A et al (2017) Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma. Ann Gastroenterol 30:571\u2013577","journal-title":"Ann Gastroenterol"},{"key":"2383_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.hpb.2017.10.016","volume":"20","author":"L Courtin-Tanguy","year":"2018","unstructured":"Courtin-Tanguy L, Turrini O, Bergeat D et al (2018) Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma. HPB (Oxford) 20:405\u2013410","journal-title":"HPB (Oxford)"},{"key":"2383_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1457496919832150","volume":"109","author":"V Sallinen","year":"2020","unstructured":"Sallinen V, Sir\u00e9n J, M\u00e4kisalo H et al (2020) Differences in prognostic factors and recurrence patterns after curative-intent resection of perihilar and distal cholangiocarcinomas. Scand J Surg 109:219\u2013227","journal-title":"Scand J Surg"},{"key":"2383_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.asjsur.2015.07.002","volume":"40","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Liu S, Wu L, Wan T (2017) Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta-analysis of prognostic factors. Asian J Surg 40:129\u2013138","journal-title":"Asian J Surg"},{"key":"2383_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study; BILCAP study group. Lancet Oncol 20:663\u2013673","journal-title":"Lancet Oncol"},{"key":"2383_CR12","doi-asserted-by":"crossref","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, et al., European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308:147\u2013156. Erratum in: JAMA. 2012;308(18):1861.","DOI":"10.1001\/jama.2012.14674"},{"issue":"8","key":"2383_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabddelghani M, Bertaut A et al (2019) Gemictaibine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12 ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658\u2013667","journal-title":"J Clin Oncol"},{"issue":"3","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemictaibine therapy versus observation in resected bile duct tract cancer. Br J Surg 105(3):192\u2013202","journal-title":"Br J Surg"},{"issue":"18","key":"2383_CR15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH et al (2022) Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol 40(18):2048\u20132057","journal-title":"J Clin Oncol"},{"issue":"10372","key":"2383_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"B Nakachi","year":"2023","unstructured":"Nakachi B, Ikeda M, Konishi M et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401(10372):195\u2013203","journal-title":"Lancet"},{"key":"2383_CR17","unstructured":"Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatobiliary Cancers. Version 1.2020. National Comprehensive Cancer Network\u00ae (NCCN\u00ae). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf (log-in required). Accessed 20 Feb 2022."},{"issue":"12","key":"2383_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"R Shroff","year":"2019","unstructured":"Shroff R, Kennedy E, Bachini M et al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 37(12):1015\u20131027","journal-title":"J Clin Oncol"},{"issue":"2","key":"2383_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(2):127\u2013140","journal-title":"Ann Oncol"},{"key":"2383_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.critrevonc.2019.09.002","volume":"143","author":"C Messina","year":"2019","unstructured":"Messina C, Merz V, Frisinghelli M et al (2019) Adjuvant chemotherapy in resected bile duct cancer: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol 143:124\u2013129","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Was H, Palmer D et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"key":"2383_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park S, Chang HM et al (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13:181\u2013188","journal-title":"Lancet Oncol"},{"key":"2383_CR23","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1007\/s11605-018-3875-x","volume":"22","author":"C Hester","year":"2018","unstructured":"Hester C, Nassour I, Adams-Huet B et al (2018) Improved survival in surgically resected distal cholangiocarcinoma treated with adjuvant therapy: a propensity score matched analysis. J Gastrointest Surg 22:2080\u20132087","journal-title":"J Gastrointest Surg"},{"key":"2383_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00423-018-1702-1","volume":"403","author":"D Bergeat","year":"2018","unstructured":"Bergeat D, Turrini O, Courtin-Tanguy L et al (2018) Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg 403:701\u2013709","journal-title":"Langenbecks Arch Surg"},{"key":"2383_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"key":"2383_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7:16","journal-title":"BMC Med Inform Decis Mak"},{"issue":"121","key":"2383_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jclinepi.2020.01.008","volume":"28","author":"J Clark","year":"2020","unstructured":"Clark J, Glasziou P, Del Mar C, Bannach-Brown A, Stehlik P, Scott AM (2020) A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol 28(121):81\u201390","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2383_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u2013716","journal-title":"ANZ J Surg"},{"issue":"24","key":"2383_CR29","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815\u20132834","journal-title":"Stat Med"},{"key":"2383_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:7","journal-title":"Trials"},{"key":"2383_CR31","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"2383_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamasurg.2016.3466","volume":"152","author":"JL Williams","year":"2017","unstructured":"Williams JL, Chan CK, Toste PA et al (2017) Association of histopathologic phenotype of periampullary adenocarcinomas with survival. JAMA Surg 152:82\u201388","journal-title":"JAMA Surg"},{"key":"2383_CR34","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/sim.1752","volume":"23","author":"JP Higgins","year":"2004","unstructured":"Higgins JP, Thompson SG (2004) Controlling the risk from spurious findings from meta-regression. Stat Med 23:1663\u20131682","journal-title":"Stat Med"},{"key":"2383_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"issue":"4","key":"2383_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088\u20131101","journal-title":"Biometrics"},{"issue":"4","key":"2383_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/01.COC.0000026833.73428.1F","volume":"26","author":"DE Heron","year":"2003","unstructured":"Heron DE, Stein DE, Eschelman DJ et al (2003) Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol 26(4):422\u2013428","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijrobp.2006.11.048","volume":"68","author":"MA Hughes","year":"2007","unstructured":"Hughes MA, Frassica DA, Yeo CJ et al (2007) Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 68(1):178\u2013182","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2383_CR39","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00280-016-3014-x","volume":"77","author":"YS Kim","year":"2016","unstructured":"Kim YS, Hwang IG, Park SE et al (2016) Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemother Pharmacol 77(5):979\u2013985","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"2383_CR40","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1245\/s10434-017-6095-9","volume":"24","author":"BL Ecker","year":"2017","unstructured":"Ecker BL, Vining CC, Roses RE et al (2017) Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis. Ann Surg Oncol 24(13):3926\u20133933","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2383_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jamcollsurg.2016.12.006","volume":"224","author":"CG Ethun","year":"2017","unstructured":"Ethun CG, Lopez-Aguiar AG, Pawlik TM et al (2017) Distal cholangiocarcinoma and pancreas adenocarcinoma: are they really the same disease? A 13-institution study from the US extrahepatic biliary malignancy consortium and the Central Pancreas Consortium. J Am Coll Surg 224(4):406\u2013413","journal-title":"J Am Coll Surg"},{"issue":"11","key":"2383_CR42","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.hpb.2019.03.363","volume":"21","author":"L Bolm","year":"2019","unstructured":"Bolm L, Petrova E, Weitz J et al (2019) Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19\u20139 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB 21(11):1513\u20131519","journal-title":"HPB"},{"issue":"6","key":"2383_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000499050","volume":"96","author":"S Hoshimoto","year":"2019","unstructured":"Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Ogata Y (2019) Association of preoperative platelet-to-lymphocyte ratio with poor outcome in patients with distal cholangiocarcinoma. Oncology 96(6):290\u2013298","journal-title":"Oncology"},{"issue":"7","key":"2383_CR44","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","volume":"58","author":"M Strijker","year":"2019","unstructured":"Strijker M, Belkouz A, van der Geest LG et al (2019) Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol 58(7):1048\u20131055","journal-title":"Acta Oncol"},{"key":"2383_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.radonc.2020.03.017","volume":"147","author":"W Zhou","year":"2020","unstructured":"Zhou W, Qian L, Rong Y et al (2020) Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol 147:111\u2013117","journal-title":"Radiother Oncol"},{"issue":"2","key":"2383_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijrobp.2021.05.012","volume":"111","author":"WI Chang","year":"2021","unstructured":"Chang WI, Kim BH, Kang HC et al (2021) The role of adjuvant chemoradiotherapy in nonhilar extrahepatic bile duct cancer: a long-term single-institution analysis. Int J Radiat Oncol Biol Phys 111(2):395\u2013404","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2383_CR47","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/cncr.33356","volume":"127","author":"SK Kamarajah","year":"2021","unstructured":"Kamarajah SK, Bednar F, Cho CS, Nathan H (2021) Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: a propensity-matched National Cancer Database analysis. Cancer 127(8):1266\u20131274","journal-title":"Cancer"},{"issue":"9","key":"2383_CR48","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.hpb.2022.01.009","volume":"24","author":"EJ de Jong","year":"2022","unstructured":"de Jong EJ, van der Geest LG, Besselink MG et al (2022) Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. HPB 24(9):1433\u20131442","journal-title":"HPB"},{"issue":"4","key":"2383_CR49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jso.27146","volume":"127","author":"JJ Hou","year":"2023","unstructured":"Hou JJ, Maithel SK, Weber SM et al (2023) Impact of adjuvant therapy on outcomes after curative-intent resection for distal cholangiocarcinoma. J Surg Oncol 127(4):607\u2013615","journal-title":"J Surg Oncol"},{"issue":"8","key":"2383_CR50","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1245\/s10434-023-13533-0","volume":"30","author":"R Macfie","year":"2023","unstructured":"Macfie R, Berger Y, Liu H et al (2023) Major postoperative complications limit adjuvant therapy administration in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma or pancreatic ductal adenocarcinoma. Ann Surg Oncol 30(8):5027\u20135034","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2383_CR51","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1097\/SLA.0000000000005012","volume":"277","author":"C Tjaden","year":"2023","unstructured":"Tjaden C, Hinz U, Klaiber U et al (2023) Distal bile duct cancer: radical (R0 > 1 mm) resection achieves favorable survival. Ann Surg 277(1):e112\u2013e118","journal-title":"Ann Surg"},{"issue":"3","key":"2383_CR52","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1097\/SLA.0000000000005743","volume":"278","author":"BA Uijterwijk","year":"2023","unstructured":"Uijterwijk BA, Lemmers DH, Bolm L et al (2023) Long-term outcomes after laparoscopic, robotic, and open pancreatoduodenectomy for distal cholangiocarcinoma: an international propensity score-matched cohort study. Ann Surg 278(3):e570\u2013e579","journal-title":"Ann Surg"},{"issue":"1","key":"2383_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12957-024-03393-7","volume":"22","author":"C Poiraud","year":"2024","unstructured":"Poiraud C, Lenne X, Bruandet A et al (2024) Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. World J Surg Oncol. 22(1):123","journal-title":"World J Surg Oncol."},{"key":"2383_CR54","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","volume":"77","author":"H Jeong","year":"2023","unstructured":"Jeong H, Kim K, Jeong JH et al (2023) Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology 77:1540\u20131549","journal-title":"Hepatology"},{"key":"2383_CR55","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT02170090?term=ACTICCA-1&rank=1"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02383-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02383-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02383-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:04:11Z","timestamp":1771275851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02383-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02383-y","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LR received consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Guerbet, Incyte, Ipsen, Roche, Servier; travel expenses from AstraZeneca; and institutional research funding from AbbVie, Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, Zymeworks. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a meta-analysis of previously published studies and does not involve any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable, as this study is a meta-analysis of previously published data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}